logo-loader
RNS
Invesco Ltd

Invesco Ltd: Form 8.3 - Xeris Pharmaceutical Inc

                        

Form 8.3

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

  1. KEY INFORMATION

Name of person dealing (Note 1)Invesco Ltd.
Company dealt inXeris Pharmaceuticals, Inc.
Class of relevant security to which the dealings being disclosed relate (Note 2)Common Stock US98422L1070
Date of dealing15-9-2021
  1. INTERESTS AND SHORT POSITIONS

(a)    Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

 LongShort
 Number (%)Number       (%)
(1) Relevant securities2,036,863         3.063%      
(2) Derivatives (other than options)  
(3) Options and agreements to purchase/sell  
Total2,036,863 3.063% Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)


 

 

Class of relevant security:LongShort
 No. (%)Number       (%)
(1) Relevant securities  


(2) Derivatives (other than options)
  


(3) Options and agreements to purchase/sell
  
Total  

        

1.    DEALINGS (Note 4)


(a)    Purchases and sales



Purchase/sale


Number of relevant securities


Price per unit (Note 52
Purchase422.55 USD
   
   

(b)    Derivatives transactions (other than options transactions)

Product name,

e.g. CFD
Nature of transaction

(Note 6)
Number of relevant securities

(Note 7)
Price per unit

(Note 5)
    

(c)    Options transactions in respect of existing relevant securities

(i)    Writing, selling, purchasing or varying

Product name,
e.g. call option
Writing, selling, purchasing, varying etc.Number of securities to which the option relates (Note 7)Exercise priceType, e.g. American, European etc.Expiry dateOption money paid/received per unit (Note 5)
       

(ii)    Exercising

Product name,

e.g. call option
Number of securitiesExercise price per unit (Note 5)
   

(d)    Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction

(Note 8)
DetailsPrice per unit

(if applicable) (Note 5)
   

    2.    OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

Is a Supplemental Form 8 attached? (Note 9)                                            NO

Date of disclosure16-09-2021
Contact nameCaroline Hellriegel
Telephone number+01 713 214 1993
If a connected EFM, name of offeree/offeror with which connectedN/A
If a connected EFM, state nature of connection (Note 10) 


NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

2 min read